Advertisement

Topics

Merck extends its lead in immuno-oncology with ‘practice-changing’ lung cancer data

09:30 EDT 16 Apr 2018 | STAT

Newly diagnosed lung cancer patients are half as likely to die of the disease if they take Keytruda drug alongside standard chemotherapy, according to data released Monday.

Original Article: Merck extends its lead in immuno-oncology with ‘practice-changing’ lung cancer data

NEXT ARTICLE

More From BioPortfolio on "Merck extends its lead in immuno-oncology with ‘practice-changing’ lung cancer data"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...